Asset Details
Do you wish to reserve the book?
Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia
Do you wish to request the book?
Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia
2015
Overview
An increasing number of private clinics in Australia are marketing and providing autologous stem cell therapies to patients. Although advocates point to the importance of medical innovation and the primacy of patient choice, these arguments are unconvincing. First, it is a stark truth that these clinics are flourishing while the efficacy and safety of autologous stem cell therapies, outside of established indications for hematopioetic stem cell transplantation, are yet to be shown. Second, few of these therapies are offered within clinical trials. Third, patients with chronic and debilitating illnesses, who are often the ones who take up these therapies, incur significant financial burdens in the expectation of benefiting from these treatments. Finally, the provision of these stem cell therapies does not follow the established pathways for legitimate medical advancement. We argue that greater regulatory oversight and professional action are necessary to protect vulnerable patients and that at this time the provision of unproven stem cell therapies outside of clinical trials is unethical.
Publisher
BioMed Central,BioMed Central Ltd
Subject
/ Biomedical and Life Sciences
/ Biomedical Engineering and Bioengineering
/ Cell- and Tissue-Based Therapy
/ Humans
/ Regenerative Medicine/Tissue Engineering
/ Review
/ Stem Cell Transplantation - economics
/ Stem Cell Transplantation - ethics
